



IsoPlexis to Participate in Webcast on Making a Name in Cancer Immunotherapy

Branford, CT (June 2017)—Sean Mackay, Co-Founder, Chief Executive Officer and Director of IsoPlexis will participate in a BioPharma Dealmakers webcast featuring three other companies innovating cancer immunotherapy. The webcast, part of the BioPharma Dealmakers series, is scheduled for 11:00 am EDT on June 13th.



[> Webcast registration link](#)

This webcast will feature a range of cancer immunotherapy innovations and explain how they are advancing progress within immuno-oncology. Technologies covered within the webcast will include: Bioclones, differentiated bispecific antibody therapeutics; LAMP-Vax, a unique immunotherapy platform creating DNA-based vaccines; targeted radioimmunotherapies, antibodies delivering radioisotopes and a precision engineering platform IsoCode for predictive cell response.

The webcast will conclude with a live roundtable discussion and a Q&A section to allow you to participate and put your own questions to the speakers.

Sean Mackay is an experienced entrepreneur, specializing in the convergence of life sciences and health care delivery. In partnership with co-founders at Yale and Caltech, Sean led IsoPlexis through foundational licensing and capital raising, while building a scientific and engineering team to develop applications and product. At IsoPlexis, Sean has enabled the development of multiple academic and biopharmaceutical collaborations in immuno-oncology patient response detection to advance single-cell precision medicine solutions in this fast-moving field.

Other webcast participants include:

- **Sia Anagnostou**, Senior Director of Corporate Development, Immunomic Therapeutics, Inc
- **Prof. Ton Logtenberg**, Founder and Chief Executive Officer, Merus N.V.
- **Dr. Mark Berger**, Chief Medical Officer, Actinium Pharmaceuticals, Inc.
- **Moderator: Raveena Bhambra**, Editor of *BioPharma Dealmakers*. Raveena has worked in the biopharma industry for over 10 years specifically in the areas of dealmaking, partnering and licensing.

About the Webcast

[BioPharma Dealmakers webcasts](#) are dedicated to small and large companies looking for commercial partnerships. Read the quarterly [BioPharma Dealmakers supplement](#) in *Nature Biotechnology* and *Nature Reviews Drug Discovery*.



About IsoPlexis

IsoPlexis is a life sciences company committed to advancing groundbreaking research and therapeutic development in immunology, oncology and other emerging disease areas. The IsoPlexis cellular response analysis platform was developed by scientific leaders at Yale and Caltech. By isolating single immune cells and analyzing their functional omic response, the platform can assess safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development and patient outcomes. Through collaborations with leading pharmaceutical companies and academic labs, the IsoPlexis technology is improving the targeting of breakthrough treatments. The venture capital-funded Yale spinout is headquartered in Branford, Connecticut.

For additional information on IsoPlexis, visit <http://www.isoplexis.com> or email info@isoplexis.com.

Contact:

Kate Ackerman, kackerman@gpg.com, 202-292-6970.